Project Grant R01CA304089
Award Date 6/19/26
Completion Date 5/31/31
Dollars Obligated $748K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $730,097 to the Sloan-Kettering Institute for Cancer Research, effective May 1, 2026 through April 30, 2031, under the Cancer Treatment Research program (CFDA 93.395). This research project addresses the suppression of anti-tumor T-cell immunity in gastric adenocarcinoma by investigating how chronic inflammation induces KLF-2 (Krüppel-like factor 2)—a quiescence-associated transcription factor—in...
- Federal Grant Award Summary The National Cancer Institute awarded a $671,252 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Biology Research program (CFDA 93.396) to investigate the mechanisms of anti-tumor immunity mediated by immune cell triads. The research project, effective from July 1, 2026 through June 30, 2031, will advance fundamental understanding of how CD4 T cells, CD8 T cells, and dendritic cells must spatially organize and interact within tumors...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Grant Award Summary The National Cancer Institute (NCI), under its Cancer Biology Research program (CFDA 93.396), awarded a $733,864 Project Grant to the Beckman Research Institute of the City of Hope, effective June 1, 2026 through May 31, 2031. The award funds fundamental research to identify and characterize stimulatory immune checkpoints that regulate macrophage-mediated programmed cell removal (PRCR), a critical process in tumor immunosurveillance and cancer elimination. Using...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Broad Institute, Inc. a Project Grant of $245,297 effective July 1, 2026, through June 30, 2029, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award supports research to develop chimeric molecules that generate neoantigens from proteins dysregulated in cancer and infectious disease. The project involves constructing bifunctional molecules by combining clinical-grade protein binders with...
- Federal Grant Award Summary The National Cancer Institute awarded a Project Grant of $648,626 to the University of California, Irvine, effective April 2, 2026, through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This award supports research investigating the mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy (CBI), specifically how programmed death receptor 1 (PD-1) blockade affects tumor microenvironments. The research seeks to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $716,521 to Sloan-Kettering Institute for Cancer Research on August 25, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports the development and clinical evaluation of DLL3-targeted IL18-secreting chimeric antigen receptor (CAR) T cells for treating small cell lung cancer (SCLC). The research initiative addresses a critical clinical need, as SCLC currently demonstrates...
- Federal Grant Award Summary Yale University received a $167,771 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded August 1, 2025, with completion targeted for July 31, 2027. The award supports research to elucidate the mechanisms of a novel human-specific immune checkpoint interaction between SIGLEC-7 and VSIG4 proteins. The research will utilize a humanized mouse platform (MISTRG6-A2) to develop in vivo models that investigate how...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $694,015 to the Beckman Research Institute of the City of Hope under the Cancer Biology Research program (CFDA 93.396) for a five-year Project Grant beginning July 1, 2026, and concluding June 30, 2031. The award funds fundamental research focused on identifying and targeting cancer immune evasion mechanisms, specifically examining how tumor-associated macrophages (TAMs) recognize and eliminate cancer cells through a process...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...